nodes	percent_of_prediction	percent_of_DWPC	metapath
Docetaxel—head and neck cancer—muscle cancer	0.269	0.619	CtDrD
Docetaxel—lung cancer—muscle cancer	0.165	0.381	CtDrD
Docetaxel—TUBB2A—Vincristine—muscle cancer	0.0297	0.0691	CbGbCtD
Docetaxel—TUBB6—Vincristine—muscle cancer	0.0297	0.0691	CbGbCtD
Docetaxel—TUBB8—Vincristine—muscle cancer	0.0297	0.0691	CbGbCtD
Docetaxel—TUBB3—Vincristine—muscle cancer	0.0297	0.0691	CbGbCtD
Docetaxel—TUBB4A—Vincristine—muscle cancer	0.0297	0.0691	CbGbCtD
Docetaxel—TUBB2B—Vincristine—muscle cancer	0.0297	0.0691	CbGbCtD
Docetaxel—TUBB4B—Vincristine—muscle cancer	0.0248	0.0578	CbGbCtD
Docetaxel—TUBB1—Vincristine—muscle cancer	0.0248	0.0578	CbGbCtD
Docetaxel—TUBB—Vincristine—muscle cancer	0.0248	0.0578	CbGbCtD
Docetaxel—ABCC10—Vincristine—muscle cancer	0.019	0.0441	CbGbCtD
Docetaxel—ABCC10—Etoposide—muscle cancer	0.0174	0.0405	CbGbCtD
Docetaxel—ABCC1—Dactinomycin—muscle cancer	0.0119	0.0277	CbGbCtD
Docetaxel—ABCC10—Doxorubicin—muscle cancer	0.0119	0.0276	CbGbCtD
Docetaxel—ABCC10—Methotrexate—muscle cancer	0.0115	0.0267	CbGbCtD
Docetaxel—ABCG2—Dactinomycin—muscle cancer	0.00795	0.0185	CbGbCtD
Docetaxel—ABCC1—Vincristine—muscle cancer	0.00732	0.017	CbGbCtD
Docetaxel—ABCC1—Etoposide—muscle cancer	0.00671	0.0156	CbGbCtD
Docetaxel—CYP1B1—Doxorubicin—muscle cancer	0.00644	0.015	CbGbCtD
Docetaxel—SLCO1B3—Methotrexate—muscle cancer	0.00641	0.0149	CbGbCtD
Docetaxel—SLC22A7—Methotrexate—muscle cancer	0.00564	0.0131	CbGbCtD
Docetaxel—ABCC2—Vincristine—muscle cancer	0.00542	0.0126	CbGbCtD
Docetaxel—ABCC2—Etoposide—muscle cancer	0.00497	0.0116	CbGbCtD
Docetaxel—ABCG2—Vincristine—muscle cancer	0.0049	0.0114	CbGbCtD
Docetaxel—ABCC1—Doxorubicin—muscle cancer	0.00458	0.0107	CbGbCtD
Docetaxel—ABCG2—Etoposide—muscle cancer	0.00449	0.0105	CbGbCtD
Docetaxel—ABCC1—Methotrexate—muscle cancer	0.00443	0.0103	CbGbCtD
Docetaxel—CYP3A7—Vincristine—muscle cancer	0.00362	0.00842	CbGbCtD
Docetaxel—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.00362	0.00842	CbGbCtD
Docetaxel—ABCC2—Doxorubicin—muscle cancer	0.00339	0.00789	CbGbCtD
Docetaxel—ABCC2—Methotrexate—muscle cancer	0.00328	0.00764	CbGbCtD
Docetaxel—ABCG2—Doxorubicin—muscle cancer	0.00306	0.00713	CbGbCtD
Docetaxel—ABCG2—Methotrexate—muscle cancer	0.00297	0.00691	CbGbCtD
Docetaxel—ABCB1—Dactinomycin—muscle cancer	0.00287	0.00668	CbGbCtD
Docetaxel—CYP3A5—Vincristine—muscle cancer	0.00271	0.00632	CbGbCtD
Docetaxel—CYP3A5—Etoposide—muscle cancer	0.00249	0.00579	CbGbCtD
Docetaxel—ABCB1—Vincristine—muscle cancer	0.00177	0.00411	CbGbCtD
Docetaxel—ABCB1—Etoposide—muscle cancer	0.00162	0.00377	CbGbCtD
Docetaxel—KIF11—embryo—muscle cancer	0.0016	0.0475	CbGeAlD
Docetaxel—ABCB1—Doxorubicin—muscle cancer	0.0011	0.00257	CbGbCtD
Docetaxel—ABCB1—Methotrexate—muscle cancer	0.00107	0.00249	CbGbCtD
Docetaxel—CYP3A4—Vincristine—muscle cancer	0.00106	0.00246	CbGbCtD
Docetaxel—CYP3A4—Etoposide—muscle cancer	0.00097	0.00226	CbGbCtD
Docetaxel—KIF11—Teniposide—Etoposide—muscle cancer	0.000962	0.592	CbGdCrCtD
Docetaxel—GHRHR—head—muscle cancer	0.000952	0.0283	CbGeAlD
Docetaxel—KIF11—tendon—muscle cancer	0.000944	0.028	CbGeAlD
Docetaxel—KIF11—bone marrow—muscle cancer	0.000915	0.0272	CbGeAlD
Docetaxel—KIF11—vagina—muscle cancer	0.000876	0.026	CbGeAlD
Docetaxel—KIF11—testis—muscle cancer	0.000782	0.0232	CbGeAlD
Docetaxel—MAP4—embryo—muscle cancer	0.000737	0.0219	CbGeAlD
Docetaxel—KIF11—Vinblastine—Vincristine—muscle cancer	0.000662	0.408	CbGdCrCtD
Docetaxel—CYP3A4—Doxorubicin—muscle cancer	0.000661	0.00154	CbGbCtD
Docetaxel—MAP2—embryo—muscle cancer	0.00058	0.0172	CbGeAlD
Docetaxel—NR1I2—head—muscle cancer	0.00057	0.0169	CbGeAlD
Docetaxel—MAP4—renal system—muscle cancer	0.000558	0.0166	CbGeAlD
Docetaxel—MAPT—tendon—muscle cancer	0.000554	0.0164	CbGeAlD
Docetaxel—TUBB8—head—muscle cancer	0.000547	0.0162	CbGeAlD
Docetaxel—TUBB8—testis—muscle cancer	0.000528	0.0157	CbGeAlD
Docetaxel—BCL2—smooth muscle tissue—muscle cancer	0.000527	0.0156	CbGeAlD
Docetaxel—BCL2—renal system—muscle cancer	0.000507	0.015	CbGeAlD
Docetaxel—MAPT—testis—muscle cancer	0.000458	0.0136	CbGeAlD
Docetaxel—TUBB4A—embryo—muscle cancer	0.000448	0.0133	CbGeAlD
Docetaxel—MAP4—tendon—muscle cancer	0.000435	0.0129	CbGeAlD
Docetaxel—TUBB1—bone marrow—muscle cancer	0.000412	0.0122	CbGeAlD
Docetaxel—MAP4—vagina—muscle cancer	0.000404	0.012	CbGeAlD
Docetaxel—MAP2—cardiac atrium—muscle cancer	0.000393	0.0117	CbGeAlD
Docetaxel—BCL2—bone marrow—muscle cancer	0.000383	0.0114	CbGeAlD
Docetaxel—SLC22A7—renal system—muscle cancer	0.00038	0.0113	CbGeAlD
Docetaxel—TUBB3—head—muscle cancer	0.000373	0.0111	CbGeAlD
Docetaxel—MAP4—head—muscle cancer	0.000373	0.0111	CbGeAlD
Docetaxel—TUBB1—head—muscle cancer	0.000365	0.0108	CbGeAlD
Docetaxel—TUBB3—testis—muscle cancer	0.00036	0.0107	CbGeAlD
Docetaxel—MAP4—testis—muscle cancer	0.00036	0.0107	CbGeAlD
Docetaxel—SLCO1B3—vagina—muscle cancer	0.000354	0.0105	CbGeAlD
Docetaxel—TUBB1—testis—muscle cancer	0.000352	0.0105	CbGeAlD
Docetaxel—TUBB4B—embryo—muscle cancer	0.00035	0.0104	CbGeAlD
Docetaxel—MAP2—tendon—muscle cancer	0.000343	0.0102	CbGeAlD
Docetaxel—TUBB4A—renal system—muscle cancer	0.000339	0.0101	CbGeAlD
Docetaxel—BCL2—head—muscle cancer	0.000339	0.0101	CbGeAlD
Docetaxel—TUBB2B—renal system—muscle cancer	0.000328	0.00974	CbGeAlD
Docetaxel—BCL2—testis—muscle cancer	0.000328	0.00973	CbGeAlD
Docetaxel—EGFR—testis—muscle cancer	0.000324	0.00961	CbGeAlD
Docetaxel—TUBB—smooth muscle tissue—muscle cancer	0.000322	0.00957	CbGeAlD
Docetaxel—TUBB2A—smooth muscle tissue—muscle cancer	0.000321	0.00952	CbGeAlD
Docetaxel—MAP2—vagina—muscle cancer	0.000318	0.00944	CbGeAlD
Docetaxel—TUBB6—smooth muscle tissue—muscle cancer	0.000316	0.00939	CbGeAlD
Docetaxel—TUBB6—renal system—muscle cancer	0.000304	0.00904	CbGeAlD
Docetaxel—MAP2—head—muscle cancer	0.000294	0.00872	CbGeAlD
Docetaxel—TUBB2B—cardiac atrium—muscle cancer	0.000294	0.00872	CbGeAlD
Docetaxel—MAP2—testis—muscle cancer	0.000284	0.00843	CbGeAlD
Docetaxel—TUBB—cardiac atrium—muscle cancer	0.000278	0.00825	CbGeAlD
Docetaxel—TUBB2A—cardiac atrium—muscle cancer	0.000276	0.00821	CbGeAlD
Docetaxel—TUBB4B—smooth muscle tissue—muscle cancer	0.000275	0.00816	CbGeAlD
Docetaxel—TUBB6—cardiac atrium—muscle cancer	0.000273	0.0081	CbGeAlD
Docetaxel—ABCC10—renal system—muscle cancer	0.000267	0.00791	CbGeAlD
Docetaxel—TUBB4A—tendon—muscle cancer	0.000265	0.00786	CbGeAlD
Docetaxel—TUBB4B—renal system—muscle cancer	0.000265	0.00786	CbGeAlD
Docetaxel—TUBB2B—tendon—muscle cancer	0.000256	0.0076	CbGeAlD
Docetaxel—SLC22A7—testis—muscle cancer	0.000245	0.00728	CbGeAlD
Docetaxel—TUBB—tendon—muscle cancer	0.000242	0.00719	CbGeAlD
Docetaxel—TUBB2A—tendon—muscle cancer	0.000241	0.00715	CbGeAlD
Docetaxel—ABCC10—cardiac atrium—muscle cancer	0.000239	0.00709	CbGeAlD
Docetaxel—TUBB6—tendon—muscle cancer	0.000238	0.00706	CbGeAlD
Docetaxel—TUBB2B—vagina—muscle cancer	0.000238	0.00705	CbGeAlD
Docetaxel—TUBB4B—cardiac atrium—muscle cancer	0.000237	0.00704	CbGeAlD
Docetaxel—TUBB—bone marrow—muscle cancer	0.000235	0.00697	CbGeAlD
Docetaxel—TUBB2A—bone marrow—muscle cancer	0.000233	0.00693	CbGeAlD
Docetaxel—TUBB6—bone marrow—muscle cancer	0.00023	0.00683	CbGeAlD
Docetaxel—TUBB4A—head—muscle cancer	0.000227	0.00674	CbGeAlD
Docetaxel—TUBB—vagina—muscle cancer	0.000225	0.00667	CbGeAlD
Docetaxel—TUBB2A—vagina—muscle cancer	0.000224	0.00664	CbGeAlD
Docetaxel—TUBB6—vagina—muscle cancer	0.000221	0.00655	CbGeAlD
Docetaxel—TUBB2B—head—muscle cancer	0.000219	0.00651	CbGeAlD
Docetaxel—TUBB4A—testis—muscle cancer	0.000219	0.00651	CbGeAlD
Docetaxel—CYP1B1—smooth muscle tissue—muscle cancer	0.000218	0.00647	CbGeAlD
Docetaxel—ABCC2—renal system—muscle cancer	0.000214	0.00636	CbGeAlD
Docetaxel—TUBB2B—testis—muscle cancer	0.000212	0.00629	CbGeAlD
Docetaxel—CYP1B1—renal system—muscle cancer	0.00021	0.00622	CbGeAlD
Docetaxel—ABCC10—tendon—muscle cancer	0.000208	0.00618	CbGeAlD
Docetaxel—TUBB4B—tendon—muscle cancer	0.000207	0.00613	CbGeAlD
Docetaxel—TUBB2A—head—muscle cancer	0.000207	0.00613	CbGeAlD
Docetaxel—TUBB6—head—muscle cancer	0.000204	0.00605	CbGeAlD
Docetaxel—ABCC10—bone marrow—muscle cancer	0.000202	0.00598	CbGeAlD
Docetaxel—TUBB—testis—muscle cancer	0.000201	0.00596	CbGeAlD
Docetaxel—TUBB4B—bone marrow—muscle cancer	0.0002	0.00594	CbGeAlD
Docetaxel—TUBB2A—testis—muscle cancer	0.0002	0.00592	CbGeAlD
Docetaxel—TUBB6—testis—muscle cancer	0.000197	0.00584	CbGeAlD
Docetaxel—ABCC10—vagina—muscle cancer	0.000193	0.00573	CbGeAlD
Docetaxel—TUBB4B—vagina—muscle cancer	0.000192	0.00569	CbGeAlD
Docetaxel—TUBB4B—head—muscle cancer	0.000177	0.00526	CbGeAlD
Docetaxel—ABCC10—testis—muscle cancer	0.000172	0.00512	CbGeAlD
Docetaxel—TUBB4B—testis—muscle cancer	0.000171	0.00508	CbGeAlD
Docetaxel—ABCC1—cardiac atrium—muscle cancer	0.000169	0.00501	CbGeAlD
Docetaxel—ABCC2—tendon—muscle cancer	0.000167	0.00496	CbGeAlD
Docetaxel—CYP1B1—tendon—muscle cancer	0.000164	0.00486	CbGeAlD
Docetaxel—ABCC1—tendon—muscle cancer	0.000147	0.00437	CbGeAlD
Docetaxel—CYP3A5—renal system—muscle cancer	0.000145	0.0043	CbGeAlD
Docetaxel—CYP1B1—head—muscle cancer	0.00014	0.00416	CbGeAlD
Docetaxel—ABCC2—testis—muscle cancer	0.000138	0.00411	CbGeAlD
Docetaxel—ABCC1—vagina—muscle cancer	0.000137	0.00405	CbGeAlD
Docetaxel—CYP1B1—testis—muscle cancer	0.000135	0.00402	CbGeAlD
Docetaxel—ABCC1—testis—muscle cancer	0.000122	0.00362	CbGeAlD
Docetaxel—ABCG2—bone marrow—muscle cancer	0.000118	0.0035	CbGeAlD
Docetaxel—ABCG2—vagina—muscle cancer	0.000113	0.00336	CbGeAlD
Docetaxel—CYP3A4—renal system—muscle cancer	0.000109	0.00323	CbGeAlD
Docetaxel—CYP3A5—vagina—muscle cancer	0.000105	0.00312	CbGeAlD
Docetaxel—ABCB1—embryo—muscle cancer	0.000102	0.00302	CbGeAlD
Docetaxel—ABCG2—testis—muscle cancer	0.000101	0.003	CbGeAlD
Docetaxel—ABCB1—renal system—muscle cancer	7.7e-05	0.00229	CbGeAlD
Docetaxel—Renal impairment—Doxorubicin—muscle cancer	6.66e-05	0.000901	CcSEcCtD
Docetaxel—Paraesthesia—Vincristine—muscle cancer	6.66e-05	0.000901	CcSEcCtD
Docetaxel—Dermatitis bullous—Doxorubicin—muscle cancer	6.63e-05	0.000898	CcSEcCtD
Docetaxel—Breast disorder—Methotrexate—muscle cancer	6.61e-05	0.000895	CcSEcCtD
Docetaxel—Toxic epidermal necrolysis—Methotrexate—muscle cancer	6.59e-05	0.000892	CcSEcCtD
Docetaxel—Leukopenia—Etoposide—muscle cancer	6.59e-05	0.000892	CcSEcCtD
Docetaxel—Body temperature increased—Dactinomycin—muscle cancer	6.56e-05	0.000888	CcSEcCtD
Docetaxel—Abdominal pain—Dactinomycin—muscle cancer	6.56e-05	0.000888	CcSEcCtD
Docetaxel—Cardiac failure—Doxorubicin—muscle cancer	6.49e-05	0.000879	CcSEcCtD
Docetaxel—Loss of consciousness—Etoposide—muscle cancer	6.47e-05	0.000875	CcSEcCtD
Docetaxel—Lethargy—Doxorubicin—muscle cancer	6.47e-05	0.000875	CcSEcCtD
Docetaxel—Decreased appetite—Vincristine—muscle cancer	6.44e-05	0.000872	CcSEcCtD
Docetaxel—Cough—Etoposide—muscle cancer	6.42e-05	0.000869	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Vincristine—muscle cancer	6.4e-05	0.000866	CcSEcCtD
Docetaxel—Fatigue—Vincristine—muscle cancer	6.39e-05	0.000865	CcSEcCtD
Docetaxel—Convulsion—Etoposide—muscle cancer	6.38e-05	0.000863	CcSEcCtD
Docetaxel—Hyponatraemia—Doxorubicin—muscle cancer	6.36e-05	0.000861	CcSEcCtD
Docetaxel—Hypertension—Etoposide—muscle cancer	6.35e-05	0.00086	CcSEcCtD
Docetaxel—Pain—Vincristine—muscle cancer	6.34e-05	0.000858	CcSEcCtD
Docetaxel—Constipation—Vincristine—muscle cancer	6.34e-05	0.000858	CcSEcCtD
Docetaxel—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	6.34e-05	0.000858	CcSEcCtD
Docetaxel—Pain in extremity—Doxorubicin—muscle cancer	6.34e-05	0.000858	CcSEcCtD
Docetaxel—Chest pain—Etoposide—muscle cancer	6.26e-05	0.000848	CcSEcCtD
Docetaxel—Migraine—Doxorubicin—muscle cancer	6.24e-05	0.000844	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	6.22e-05	0.000842	CcSEcCtD
Docetaxel—Hypersensitivity—Dactinomycin—muscle cancer	6.11e-05	0.000828	CcSEcCtD
Docetaxel—Gastrointestinal pain—Vincristine—muscle cancer	6.06e-05	0.000821	CcSEcCtD
Docetaxel—Confusional state—Etoposide—muscle cancer	6.06e-05	0.00082	CcSEcCtD
Docetaxel—Pancytopenia—Methotrexate—muscle cancer	6.01e-05	0.000813	CcSEcCtD
Docetaxel—Anaphylactic shock—Etoposide—muscle cancer	6.01e-05	0.000813	CcSEcCtD
Docetaxel—Infection—Etoposide—muscle cancer	5.97e-05	0.000808	CcSEcCtD
Docetaxel—Ataxia—Doxorubicin—muscle cancer	5.96e-05	0.000807	CcSEcCtD
Docetaxel—Asthenia—Dactinomycin—muscle cancer	5.95e-05	0.000806	CcSEcCtD
Docetaxel—Neutropenia—Methotrexate—muscle cancer	5.92e-05	0.000801	CcSEcCtD
Docetaxel—Dehydration—Doxorubicin—muscle cancer	5.89e-05	0.000798	CcSEcCtD
Docetaxel—Thrombocytopenia—Etoposide—muscle cancer	5.88e-05	0.000796	CcSEcCtD
Docetaxel—Tachycardia—Etoposide—muscle cancer	5.86e-05	0.000793	CcSEcCtD
Docetaxel—Body temperature increased—Vincristine—muscle cancer	5.86e-05	0.000793	CcSEcCtD
Docetaxel—Abdominal pain—Vincristine—muscle cancer	5.86e-05	0.000793	CcSEcCtD
Docetaxel—Liver function test abnormal—Doxorubicin—muscle cancer	5.85e-05	0.000792	CcSEcCtD
Docetaxel—Skin disorder—Etoposide—muscle cancer	5.83e-05	0.00079	CcSEcCtD
Docetaxel—ABCB1—bone marrow—muscle cancer	5.82e-05	0.00173	CbGeAlD
Docetaxel—Dry skin—Doxorubicin—muscle cancer	5.81e-05	0.000786	CcSEcCtD
Docetaxel—Orthostatic hypotension—Doxorubicin—muscle cancer	5.79e-05	0.000783	CcSEcCtD
Docetaxel—Abdominal pain upper—Doxorubicin—muscle cancer	5.79e-05	0.000783	CcSEcCtD
Docetaxel—Breast disorder—Doxorubicin—muscle cancer	5.73e-05	0.000775	CcSEcCtD
Docetaxel—Anorexia—Etoposide—muscle cancer	5.72e-05	0.000775	CcSEcCtD
Docetaxel—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	5.71e-05	0.000772	CcSEcCtD
Docetaxel—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	5.71e-05	0.000772	CcSEcCtD
Docetaxel—Diarrhoea—Dactinomycin—muscle cancer	5.68e-05	0.000768	CcSEcCtD
Docetaxel—Pneumonia—Methotrexate—muscle cancer	5.67e-05	0.000768	CcSEcCtD
Docetaxel—Nasopharyngitis—Doxorubicin—muscle cancer	5.67e-05	0.000767	CcSEcCtD
Docetaxel—Infestation NOS—Methotrexate—muscle cancer	5.64e-05	0.000763	CcSEcCtD
Docetaxel—Infestation—Methotrexate—muscle cancer	5.64e-05	0.000763	CcSEcCtD
Docetaxel—Hypotension—Etoposide—muscle cancer	5.61e-05	0.00076	CcSEcCtD
Docetaxel—Stevens-Johnson syndrome—Methotrexate—muscle cancer	5.59e-05	0.000757	CcSEcCtD
Docetaxel—Alanine aminotransferase increased—Doxorubicin—muscle cancer	5.59e-05	0.000757	CcSEcCtD
Docetaxel—ABCB1—vagina—muscle cancer	5.58e-05	0.00166	CbGeAlD
Docetaxel—Renal failure—Methotrexate—muscle cancer	5.54e-05	0.00075	CcSEcCtD
Docetaxel—Stomatitis—Methotrexate—muscle cancer	5.5e-05	0.000744	CcSEcCtD
Docetaxel—Conjunctivitis—Methotrexate—muscle cancer	5.48e-05	0.000742	CcSEcCtD
Docetaxel—Dysphagia—Doxorubicin—muscle cancer	5.48e-05	0.000741	CcSEcCtD
Docetaxel—Hypersensitivity—Vincristine—muscle cancer	5.46e-05	0.000739	CcSEcCtD
Docetaxel—Paraesthesia—Etoposide—muscle cancer	5.39e-05	0.00073	CcSEcCtD
Docetaxel—Dyspnoea—Etoposide—muscle cancer	5.35e-05	0.000725	CcSEcCtD
Docetaxel—Somnolence—Etoposide—muscle cancer	5.34e-05	0.000723	CcSEcCtD
Docetaxel—Angina pectoris—Doxorubicin—muscle cancer	5.34e-05	0.000722	CcSEcCtD
Docetaxel—Hepatobiliary disease—Methotrexate—muscle cancer	5.33e-05	0.000722	CcSEcCtD
Docetaxel—Epistaxis—Methotrexate—muscle cancer	5.32e-05	0.00072	CcSEcCtD
Docetaxel—Asthenia—Vincristine—muscle cancer	5.32e-05	0.00072	CcSEcCtD
Docetaxel—Vomiting—Dactinomycin—muscle cancer	5.28e-05	0.000714	CcSEcCtD
Docetaxel—Agranulocytosis—Methotrexate—muscle cancer	5.26e-05	0.000712	CcSEcCtD
Docetaxel—Rash—Dactinomycin—muscle cancer	5.23e-05	0.000708	CcSEcCtD
Docetaxel—Decreased appetite—Etoposide—muscle cancer	5.22e-05	0.000707	CcSEcCtD
Docetaxel—Pancytopenia—Doxorubicin—muscle cancer	5.2e-05	0.000704	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Etoposide—muscle cancer	5.18e-05	0.000702	CcSEcCtD
Docetaxel—Fatigue—Etoposide—muscle cancer	5.18e-05	0.000701	CcSEcCtD
Docetaxel—ABCB1—head—muscle cancer	5.15e-05	0.00153	CbGeAlD
Docetaxel—Constipation—Etoposide—muscle cancer	5.14e-05	0.000695	CcSEcCtD
Docetaxel—Pain—Etoposide—muscle cancer	5.14e-05	0.000695	CcSEcCtD
Docetaxel—Neutropenia—Doxorubicin—muscle cancer	5.12e-05	0.000693	CcSEcCtD
Docetaxel—Haemoglobin—Methotrexate—muscle cancer	5.09e-05	0.000689	CcSEcCtD
Docetaxel—Diarrhoea—Vincristine—muscle cancer	5.07e-05	0.000687	CcSEcCtD
Docetaxel—Haemorrhage—Methotrexate—muscle cancer	5.06e-05	0.000685	CcSEcCtD
Docetaxel—Hepatitis—Methotrexate—muscle cancer	5.06e-05	0.000685	CcSEcCtD
Docetaxel—Pharyngitis—Methotrexate—muscle cancer	5.03e-05	0.00068	CcSEcCtD
Docetaxel—Urinary tract disorder—Methotrexate—muscle cancer	5e-05	0.000677	CcSEcCtD
Docetaxel—Weight increased—Doxorubicin—muscle cancer	4.98e-05	0.000675	CcSEcCtD
Docetaxel—ABCB1—testis—muscle cancer	4.98e-05	0.00148	CbGeAlD
Docetaxel—Urethral disorder—Methotrexate—muscle cancer	4.96e-05	0.000672	CcSEcCtD
Docetaxel—Weight decreased—Doxorubicin—muscle cancer	4.96e-05	0.000671	CcSEcCtD
Docetaxel—Feeling abnormal—Etoposide—muscle cancer	4.95e-05	0.00067	CcSEcCtD
Docetaxel—Nausea—Dactinomycin—muscle cancer	4.93e-05	0.000667	CcSEcCtD
Docetaxel—Pneumonia—Doxorubicin—muscle cancer	4.91e-05	0.000665	CcSEcCtD
Docetaxel—Gastrointestinal pain—Etoposide—muscle cancer	4.91e-05	0.000665	CcSEcCtD
Docetaxel—Dizziness—Vincristine—muscle cancer	4.9e-05	0.000664	CcSEcCtD
Docetaxel—Infestation NOS—Doxorubicin—muscle cancer	4.88e-05	0.000661	CcSEcCtD
Docetaxel—Infestation—Doxorubicin—muscle cancer	4.88e-05	0.000661	CcSEcCtD
Docetaxel—Visual impairment—Methotrexate—muscle cancer	4.88e-05	0.00066	CcSEcCtD
Docetaxel—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	4.84e-05	0.000655	CcSEcCtD
Docetaxel—Renal failure—Doxorubicin—muscle cancer	4.8e-05	0.00065	CcSEcCtD
Docetaxel—Erythema multiforme—Methotrexate—muscle cancer	4.79e-05	0.000648	CcSEcCtD
Docetaxel—Neuropathy peripheral—Doxorubicin—muscle cancer	4.79e-05	0.000648	CcSEcCtD
Docetaxel—EGFR—Signaling by PDGF—FOXO4—muscle cancer	4.78e-05	0.00175	CbGpPWpGaD
Docetaxel—Jaundice—Doxorubicin—muscle cancer	4.76e-05	0.000644	CcSEcCtD
Docetaxel—Stomatitis—Doxorubicin—muscle cancer	4.76e-05	0.000644	CcSEcCtD
Docetaxel—Abdominal pain—Etoposide—muscle cancer	4.75e-05	0.000643	CcSEcCtD
Docetaxel—Body temperature increased—Etoposide—muscle cancer	4.75e-05	0.000643	CcSEcCtD
Docetaxel—Conjunctivitis—Doxorubicin—muscle cancer	4.75e-05	0.000643	CcSEcCtD
Docetaxel—Eye disorder—Methotrexate—muscle cancer	4.73e-05	0.00064	CcSEcCtD
Docetaxel—Vomiting—Vincristine—muscle cancer	4.71e-05	0.000638	CcSEcCtD
Docetaxel—Cardiac disorder—Methotrexate—muscle cancer	4.7e-05	0.000636	CcSEcCtD
Docetaxel—Rash—Vincristine—muscle cancer	4.67e-05	0.000633	CcSEcCtD
Docetaxel—Dermatitis—Vincristine—muscle cancer	4.67e-05	0.000632	CcSEcCtD
Docetaxel—Headache—Vincristine—muscle cancer	4.64e-05	0.000629	CcSEcCtD
Docetaxel—Hepatobiliary disease—Doxorubicin—muscle cancer	4.62e-05	0.000625	CcSEcCtD
Docetaxel—Epistaxis—Doxorubicin—muscle cancer	4.61e-05	0.000624	CcSEcCtD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	4.6e-05	0.00168	CbGpPWpGaD
Docetaxel—KIF11—Hemostasis—VEGFA—muscle cancer	4.6e-05	0.00168	CbGpPWpGaD
Docetaxel—Angiopathy—Methotrexate—muscle cancer	4.59e-05	0.000622	CcSEcCtD
Docetaxel—GHRHR—Signaling Pathways—PTCH1—muscle cancer	4.58e-05	0.00167	CbGpPWpGaD
Docetaxel—Immune system disorder—Methotrexate—muscle cancer	4.57e-05	0.000619	CcSEcCtD
Docetaxel—Mediastinal disorder—Methotrexate—muscle cancer	4.56e-05	0.000618	CcSEcCtD
Docetaxel—Agranulocytosis—Doxorubicin—muscle cancer	4.56e-05	0.000617	CcSEcCtD
Docetaxel—Chills—Methotrexate—muscle cancer	4.54e-05	0.000615	CcSEcCtD
Docetaxel—EGFR—B Cell Activation—FOXO4—muscle cancer	4.52e-05	0.00165	CbGpPWpGaD
Docetaxel—Alopecia—Methotrexate—muscle cancer	4.47e-05	0.000606	CcSEcCtD
Docetaxel—ABCG2—Fluoropyrimidine Activity—TP53—muscle cancer	4.45e-05	0.00163	CbGpPWpGaD
Docetaxel—Mental disorder—Methotrexate—muscle cancer	4.44e-05	0.0006	CcSEcCtD
Docetaxel—Hypersensitivity—Etoposide—muscle cancer	4.42e-05	0.000599	CcSEcCtD
Docetaxel—BCL2—Direct p53 effectors—MDM2—muscle cancer	4.42e-05	0.00162	CbGpPWpGaD
Docetaxel—EGFR—PI-3K cascade—KIT—muscle cancer	4.41e-05	0.00161	CbGpPWpGaD
Docetaxel—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	4.41e-05	0.00161	CbGpPWpGaD
Docetaxel—Erythema—Methotrexate—muscle cancer	4.41e-05	0.000597	CcSEcCtD
Docetaxel—Malnutrition—Methotrexate—muscle cancer	4.41e-05	0.000597	CcSEcCtD
Docetaxel—Haemoglobin—Doxorubicin—muscle cancer	4.41e-05	0.000596	CcSEcCtD
Docetaxel—Nausea—Vincristine—muscle cancer	4.4e-05	0.000596	CcSEcCtD
Docetaxel—Rhinitis—Doxorubicin—muscle cancer	4.4e-05	0.000595	CcSEcCtD
Docetaxel—Haemorrhage—Doxorubicin—muscle cancer	4.38e-05	0.000593	CcSEcCtD
Docetaxel—Hepatitis—Doxorubicin—muscle cancer	4.38e-05	0.000593	CcSEcCtD
Docetaxel—TUBB—Cell Cycle—BUB1B—muscle cancer	4.36e-05	0.0016	CbGpPWpGaD
Docetaxel—Hypoaesthesia—Doxorubicin—muscle cancer	4.36e-05	0.00059	CcSEcCtD
Docetaxel—Pharyngitis—Doxorubicin—muscle cancer	4.35e-05	0.000589	CcSEcCtD
Docetaxel—EGFR—Signaling by SCF-KIT—FOXO1—muscle cancer	4.33e-05	0.00158	CbGpPWpGaD
Docetaxel—EGFR—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	4.33e-05	0.00158	CbGpPWpGaD
Docetaxel—Urinary tract disorder—Doxorubicin—muscle cancer	4.33e-05	0.000586	CcSEcCtD
Docetaxel—Oedema peripheral—Doxorubicin—muscle cancer	4.32e-05	0.000585	CcSEcCtD
Docetaxel—Dysgeusia—Methotrexate—muscle cancer	4.32e-05	0.000584	CcSEcCtD
Docetaxel—EGFR—PI3K/AKT activation—KIT—muscle cancer	4.31e-05	0.00158	CbGpPWpGaD
Docetaxel—Asthenia—Etoposide—muscle cancer	4.31e-05	0.000583	CcSEcCtD
Docetaxel—Connective tissue disorder—Doxorubicin—muscle cancer	4.31e-05	0.000583	CcSEcCtD
Docetaxel—Urethral disorder—Doxorubicin—muscle cancer	4.3e-05	0.000582	CcSEcCtD
Docetaxel—EGFR—GAB1 signalosome—KIT—muscle cancer	4.28e-05	0.00156	CbGpPWpGaD
Docetaxel—Back pain—Methotrexate—muscle cancer	4.26e-05	0.000577	CcSEcCtD
Docetaxel—MAPT—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	4.26e-05	0.00156	CbGpPWpGaD
Docetaxel—Pruritus—Etoposide—muscle cancer	4.25e-05	0.000575	CcSEcCtD
Docetaxel—Visual impairment—Doxorubicin—muscle cancer	4.23e-05	0.000572	CcSEcCtD
Docetaxel—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—muscle cancer	4.18e-05	0.00153	CbGpPWpGaD
Docetaxel—BCL2—Integrated Breast Cancer Pathway—MDM2—muscle cancer	4.16e-05	0.00152	CbGpPWpGaD
Docetaxel—Erythema multiforme—Doxorubicin—muscle cancer	4.15e-05	0.000561	CcSEcCtD
Docetaxel—EGFR—Downstream signaling of activated FGFR—FOXO1—muscle cancer	4.14e-05	0.00152	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways in Glioblastoma—CDKN2A—muscle cancer	4.13e-05	0.00151	CbGpPWpGaD
Docetaxel—Diarrhoea—Etoposide—muscle cancer	4.11e-05	0.000556	CcSEcCtD
Docetaxel—EGFR—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	4.1e-05	0.0015	CbGpPWpGaD
Docetaxel—Eye disorder—Doxorubicin—muscle cancer	4.1e-05	0.000555	CcSEcCtD
Docetaxel—EGFR—Signaling by ERBB4—FOXO1—muscle cancer	4.08e-05	0.00149	CbGpPWpGaD
Docetaxel—Anaemia—Methotrexate—muscle cancer	4.07e-05	0.000551	CcSEcCtD
Docetaxel—Cardiac disorder—Doxorubicin—muscle cancer	4.07e-05	0.000551	CcSEcCtD
Docetaxel—Flushing—Doxorubicin—muscle cancer	4.07e-05	0.000551	CcSEcCtD
Docetaxel—TUBB4A—Cell Cycle, Mitotic—BUB1B—muscle cancer	4.04e-05	0.00148	CbGpPWpGaD
Docetaxel—KIF11—Immune System—KIT—muscle cancer	4.03e-05	0.00147	CbGpPWpGaD
Docetaxel—EGFR—SHP2 signaling—VEGFA—muscle cancer	4.02e-05	0.00147	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways in Glioblastoma—MDM2—muscle cancer	4.01e-05	0.00147	CbGpPWpGaD
Docetaxel—NR1I2—Gene Expression—MED12—muscle cancer	3.98e-05	0.00146	CbGpPWpGaD
Docetaxel—Angiopathy—Doxorubicin—muscle cancer	3.98e-05	0.000538	CcSEcCtD
Docetaxel—Dizziness—Etoposide—muscle cancer	3.97e-05	0.000538	CcSEcCtD
Docetaxel—Immune system disorder—Doxorubicin—muscle cancer	3.96e-05	0.000536	CcSEcCtD
Docetaxel—Mediastinal disorder—Doxorubicin—muscle cancer	3.95e-05	0.000535	CcSEcCtD
Docetaxel—Leukopenia—Methotrexate—muscle cancer	3.95e-05	0.000534	CcSEcCtD
Docetaxel—GHRHR—Signaling Pathways—FOXO4—muscle cancer	3.94e-05	0.00144	CbGpPWpGaD
Docetaxel—Chills—Doxorubicin—muscle cancer	3.93e-05	0.000532	CcSEcCtD
Docetaxel—Arrhythmia—Doxorubicin—muscle cancer	3.92e-05	0.00053	CcSEcCtD
Docetaxel—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	3.91e-05	0.00143	CbGpPWpGaD
Docetaxel—EGFR—Downstream signal transduction—FOXO1—muscle cancer	3.89e-05	0.00142	CbGpPWpGaD
Docetaxel—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	3.88e-05	0.00142	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism of lipids and lipoproteins—MED12—muscle cancer	3.88e-05	0.00142	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR—FOXO1—muscle cancer	3.88e-05	0.00142	CbGpPWpGaD
Docetaxel—EGFR—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	3.88e-05	0.00142	CbGpPWpGaD
Docetaxel—Alopecia—Doxorubicin—muscle cancer	3.87e-05	0.000524	CcSEcCtD
Docetaxel—GHRHR—Signaling Pathways—CNR1—muscle cancer	3.87e-05	0.00141	CbGpPWpGaD
Docetaxel—EGFR—Constitutive PI3K/AKT Signaling in Cancer—MDM2—muscle cancer	3.86e-05	0.00141	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB2—FOXO1—muscle cancer	3.86e-05	0.00141	CbGpPWpGaD
Docetaxel—Cough—Methotrexate—muscle cancer	3.85e-05	0.000521	CcSEcCtD
Docetaxel—Mental disorder—Doxorubicin—muscle cancer	3.84e-05	0.00052	CcSEcCtD
Docetaxel—EGFR—DAP12 signaling—FOXO1—muscle cancer	3.84e-05	0.0014	CbGpPWpGaD
Docetaxel—Convulsion—Methotrexate—muscle cancer	3.82e-05	0.000517	CcSEcCtD
Docetaxel—Vomiting—Etoposide—muscle cancer	3.82e-05	0.000517	CcSEcCtD
Docetaxel—BCL2—Apoptosis—TP53—muscle cancer	3.82e-05	0.0014	CbGpPWpGaD
Docetaxel—Malnutrition—Doxorubicin—muscle cancer	3.82e-05	0.000517	CcSEcCtD
Docetaxel—Erythema—Doxorubicin—muscle cancer	3.82e-05	0.000517	CcSEcCtD
Docetaxel—MAPT—Apoptosis—TP53—muscle cancer	3.8e-05	0.00139	CbGpPWpGaD
Docetaxel—Rash—Etoposide—muscle cancer	3.79e-05	0.000513	CcSEcCtD
Docetaxel—Dermatitis—Etoposide—muscle cancer	3.78e-05	0.000512	CcSEcCtD
Docetaxel—EGFR—Downstream signaling events of B Cell Receptor (BCR)—FOXO1—muscle cancer	3.78e-05	0.00138	CbGpPWpGaD
Docetaxel—Headache—Etoposide—muscle cancer	3.76e-05	0.000509	CcSEcCtD
Docetaxel—EGFR—Androgen receptor signaling pathway—MDM2—muscle cancer	3.76e-05	0.00137	CbGpPWpGaD
Docetaxel—Myalgia—Methotrexate—muscle cancer	3.75e-05	0.000508	CcSEcCtD
Docetaxel—Arthralgia—Methotrexate—muscle cancer	3.75e-05	0.000508	CcSEcCtD
Docetaxel—Chest pain—Methotrexate—muscle cancer	3.75e-05	0.000508	CcSEcCtD
Docetaxel—Dysgeusia—Doxorubicin—muscle cancer	3.74e-05	0.000506	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	3.73e-05	0.000504	CcSEcCtD
Docetaxel—TUBB4B—Cell Cycle, Mitotic—BUB1B—muscle cancer	3.7e-05	0.00135	CbGpPWpGaD
Docetaxel—Back pain—Doxorubicin—muscle cancer	3.69e-05	0.0005	CcSEcCtD
Docetaxel—Muscle spasms—Doxorubicin—muscle cancer	3.67e-05	0.000497	CcSEcCtD
Docetaxel—Confusional state—Methotrexate—muscle cancer	3.63e-05	0.000491	CcSEcCtD
Docetaxel—TUBB4A—Cell Cycle—BUB1B—muscle cancer	3.62e-05	0.00132	CbGpPWpGaD
Docetaxel—EGFR—DAP12 interactions—FOXO1—muscle cancer	3.61e-05	0.00132	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR in disease—FOXO1—muscle cancer	3.61e-05	0.00132	CbGpPWpGaD
Docetaxel—EGFR—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	3.61e-05	0.00132	CbGpPWpGaD
Docetaxel—Anaphylactic shock—Methotrexate—muscle cancer	3.6e-05	0.000487	CcSEcCtD
Docetaxel—BCL2—Apoptosis Modulation and Signaling—TP53—muscle cancer	3.58e-05	0.00131	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR—FOXO1—muscle cancer	3.58e-05	0.00131	CbGpPWpGaD
Docetaxel—Infection—Methotrexate—muscle cancer	3.57e-05	0.000484	CcSEcCtD
Docetaxel—Nausea—Etoposide—muscle cancer	3.57e-05	0.000483	CcSEcCtD
Docetaxel—MAPT—MAPK Signaling Pathway—TP53—muscle cancer	3.57e-05	0.0013	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR in Cancer—FOXO1—muscle cancer	3.55e-05	0.0013	CbGpPWpGaD
Docetaxel—EGFR—Signaling by PDGF—FOXO1—muscle cancer	3.53e-05	0.00129	CbGpPWpGaD
Docetaxel—Nervous system disorder—Methotrexate—muscle cancer	3.53e-05	0.000478	CcSEcCtD
Docetaxel—Anaemia—Doxorubicin—muscle cancer	3.53e-05	0.000477	CcSEcCtD
Docetaxel—Thrombocytopenia—Methotrexate—muscle cancer	3.52e-05	0.000477	CcSEcCtD
Docetaxel—Skin disorder—Methotrexate—muscle cancer	3.49e-05	0.000473	CcSEcCtD
Docetaxel—EGFR—PI-3K cascade—MDM2—muscle cancer	3.48e-05	0.00127	CbGpPWpGaD
Docetaxel—KIF11—Hemostasis—TP53—muscle cancer	3.47e-05	0.00127	CbGpPWpGaD
Docetaxel—BCL2—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	3.45e-05	0.00126	CbGpPWpGaD
Docetaxel—Anorexia—Methotrexate—muscle cancer	3.43e-05	0.000464	CcSEcCtD
Docetaxel—Syncope—Doxorubicin—muscle cancer	3.42e-05	0.000463	CcSEcCtD
Docetaxel—Leukopenia—Doxorubicin—muscle cancer	3.42e-05	0.000462	CcSEcCtD
Docetaxel—EGFR—PI3K/AKT activation—MDM2—muscle cancer	3.39e-05	0.00124	CbGpPWpGaD
Docetaxel—ABCG2—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	3.38e-05	0.00124	CbGpPWpGaD
Docetaxel—Palpitations—Doxorubicin—muscle cancer	3.37e-05	0.000457	CcSEcCtD
Docetaxel—EGFR—GAB1 signalosome—MDM2—muscle cancer	3.37e-05	0.00123	CbGpPWpGaD
Docetaxel—Hypotension—Methotrexate—muscle cancer	3.36e-05	0.000455	CcSEcCtD
Docetaxel—Loss of consciousness—Doxorubicin—muscle cancer	3.35e-05	0.000454	CcSEcCtD
Docetaxel—EGFR—B Cell Activation—FOXO1—muscle cancer	3.34e-05	0.00122	CbGpPWpGaD
Docetaxel—Cough—Doxorubicin—muscle cancer	3.33e-05	0.000451	CcSEcCtD
Docetaxel—EGFR—Signaling by NGF—FOXO4—muscle cancer	3.33e-05	0.00122	CbGpPWpGaD
Docetaxel—BCL2—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	3.32e-05	0.00122	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—BUB1B—muscle cancer	3.31e-05	0.00121	CbGpPWpGaD
Docetaxel—Convulsion—Doxorubicin—muscle cancer	3.31e-05	0.000448	CcSEcCtD
Docetaxel—EGFR—Signaling by SCF-KIT—KIT—muscle cancer	3.3e-05	0.00121	CbGpPWpGaD
Docetaxel—Hypertension—Doxorubicin—muscle cancer	3.3e-05	0.000446	CcSEcCtD
Docetaxel—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—MDM2—muscle cancer	3.29e-05	0.0012	CbGpPWpGaD
Docetaxel—Musculoskeletal discomfort—Methotrexate—muscle cancer	3.28e-05	0.000444	CcSEcCtD
Docetaxel—Insomnia—Methotrexate—muscle cancer	3.25e-05	0.00044	CcSEcCtD
Docetaxel—Chest pain—Doxorubicin—muscle cancer	3.25e-05	0.00044	CcSEcCtD
Docetaxel—Myalgia—Doxorubicin—muscle cancer	3.25e-05	0.00044	CcSEcCtD
Docetaxel—Arthralgia—Doxorubicin—muscle cancer	3.25e-05	0.00044	CcSEcCtD
Docetaxel—Paraesthesia—Methotrexate—muscle cancer	3.23e-05	0.000437	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	3.23e-05	0.000437	CcSEcCtD
Docetaxel—MAPT—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	3.22e-05	0.00118	CbGpPWpGaD
Docetaxel—EGFR—ErbB Signaling Pathway—TP53—muscle cancer	3.21e-05	0.00118	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—FOXO4—muscle cancer	3.21e-05	0.00117	CbGpPWpGaD
Docetaxel—Dyspnoea—Methotrexate—muscle cancer	3.21e-05	0.000434	CcSEcCtD
Docetaxel—Somnolence—Methotrexate—muscle cancer	3.2e-05	0.000433	CcSEcCtD
Docetaxel—EGFR—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	3.2e-05	0.00117	CbGpPWpGaD
Docetaxel—BCL2—Senescence and Autophagy in Cancer—TP53—muscle cancer	3.19e-05	0.00117	CbGpPWpGaD
Docetaxel—Dry mouth—Doxorubicin—muscle cancer	3.18e-05	0.00043	CcSEcCtD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	3.18e-05	0.00116	CbGpPWpGaD
Docetaxel—KIF11—Immune System—MDM2—muscle cancer	3.17e-05	0.00116	CbGpPWpGaD
Docetaxel—Dyspepsia—Methotrexate—muscle cancer	3.17e-05	0.000429	CcSEcCtD
Docetaxel—EGFR—Developmental Biology—MYOD1—muscle cancer	3.16e-05	0.00116	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—IGF2—muscle cancer	3.16e-05	0.00116	CbGpPWpGaD
Docetaxel—BCL2—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	3.16e-05	0.00116	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling of activated FGFR—KIT—muscle cancer	3.16e-05	0.00115	CbGpPWpGaD
Docetaxel—Confusional state—Doxorubicin—muscle cancer	3.14e-05	0.000425	CcSEcCtD
Docetaxel—Decreased appetite—Methotrexate—muscle cancer	3.13e-05	0.000423	CcSEcCtD
Docetaxel—Oedema—Doxorubicin—muscle cancer	3.11e-05	0.000422	CcSEcCtD
Docetaxel—Anaphylactic shock—Doxorubicin—muscle cancer	3.11e-05	0.000422	CcSEcCtD
Docetaxel—EGFR—Signaling by ERBB4—KIT—muscle cancer	3.11e-05	0.00114	CbGpPWpGaD
Docetaxel—Gastrointestinal disorder—Methotrexate—muscle cancer	3.11e-05	0.00042	CcSEcCtD
Docetaxel—Fatigue—Methotrexate—muscle cancer	3.1e-05	0.00042	CcSEcCtD
Docetaxel—BCL2—DNA Damage Response (only ATM dependent)—TP53—muscle cancer	3.1e-05	0.00113	CbGpPWpGaD
Docetaxel—Infection—Doxorubicin—muscle cancer	3.09e-05	0.000419	CcSEcCtD
Docetaxel—Pain—Methotrexate—muscle cancer	3.08e-05	0.000416	CcSEcCtD
Docetaxel—Shock—Doxorubicin—muscle cancer	3.06e-05	0.000415	CcSEcCtD
Docetaxel—SLCO1B3—Metabolism—FH—muscle cancer	3.06e-05	0.00112	CbGpPWpGaD
Docetaxel—Nervous system disorder—Doxorubicin—muscle cancer	3.05e-05	0.000413	CcSEcCtD
Docetaxel—Thrombocytopenia—Doxorubicin—muscle cancer	3.05e-05	0.000413	CcSEcCtD
Docetaxel—Tachycardia—Doxorubicin—muscle cancer	3.04e-05	0.000411	CcSEcCtD
Docetaxel—Skin disorder—Doxorubicin—muscle cancer	3.03e-05	0.00041	CcSEcCtD
Docetaxel—Anorexia—Doxorubicin—muscle cancer	2.97e-05	0.000402	CcSEcCtD
Docetaxel—EGFR—Downstream signal transduction—KIT—muscle cancer	2.97e-05	0.00109	CbGpPWpGaD
Docetaxel—Feeling abnormal—Methotrexate—muscle cancer	2.96e-05	0.000401	CcSEcCtD
Docetaxel—EGFR—Signaling by FGFR—KIT—muscle cancer	2.95e-05	0.00108	CbGpPWpGaD
Docetaxel—TUBB6—Metabolism of proteins—IGF2—muscle cancer	2.95e-05	0.00108	CbGpPWpGaD
Docetaxel—TUBB2B—Metabolism of proteins—IGF2—muscle cancer	2.95e-05	0.00108	CbGpPWpGaD
Docetaxel—Gastrointestinal pain—Methotrexate—muscle cancer	2.94e-05	0.000398	CcSEcCtD
Docetaxel—EGFR—Signaling by ERBB2—KIT—muscle cancer	2.94e-05	0.00107	CbGpPWpGaD
Docetaxel—EGFR—DAP12 signaling—KIT—muscle cancer	2.92e-05	0.00107	CbGpPWpGaD
Docetaxel—Hypotension—Doxorubicin—muscle cancer	2.91e-05	0.000394	CcSEcCtD
Docetaxel—GHRHR—Signaling Pathways—FOXO1—muscle cancer	2.91e-05	0.00106	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—MED12—muscle cancer	2.89e-05	0.00106	CbGpPWpGaD
Docetaxel—EGFR—Spinal Cord Injury—PTGS2—muscle cancer	2.89e-05	0.00106	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	2.88e-05	0.00105	CbGpPWpGaD
Docetaxel—TUBB3—Metabolism of proteins—IGF2—muscle cancer	2.84e-05	0.00104	CbGpPWpGaD
Docetaxel—Body temperature increased—Methotrexate—muscle cancer	2.84e-05	0.000385	CcSEcCtD
Docetaxel—Abdominal pain—Methotrexate—muscle cancer	2.84e-05	0.000385	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Doxorubicin—muscle cancer	2.84e-05	0.000384	CcSEcCtD
Docetaxel—Insomnia—Doxorubicin—muscle cancer	2.82e-05	0.000381	CcSEcCtD
Docetaxel—Paraesthesia—Doxorubicin—muscle cancer	2.8e-05	0.000379	CcSEcCtD
Docetaxel—Dyspnoea—Doxorubicin—muscle cancer	2.78e-05	0.000376	CcSEcCtD
Docetaxel—Somnolence—Doxorubicin—muscle cancer	2.77e-05	0.000375	CcSEcCtD
Docetaxel—TUBB2A—Metabolism of proteins—IGF2—muscle cancer	2.76e-05	0.00101	CbGpPWpGaD
Docetaxel—BCL2—Immune System—CD34—muscle cancer	2.75e-05	0.00101	CbGpPWpGaD
Docetaxel—EGFR—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	2.75e-05	0.00101	CbGpPWpGaD
Docetaxel—EGFR—DAP12 interactions—KIT—muscle cancer	2.75e-05	0.00101	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR in disease—KIT—muscle cancer	2.75e-05	0.00101	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.74e-05	0.001	CbGpPWpGaD
Docetaxel—Dyspepsia—Doxorubicin—muscle cancer	2.74e-05	0.000371	CcSEcCtD
Docetaxel—EGFR—Signaling by EGFR—KIT—muscle cancer	2.73e-05	0.000997	CbGpPWpGaD
Docetaxel—Decreased appetite—Doxorubicin—muscle cancer	2.71e-05	0.000367	CcSEcCtD
Docetaxel—EGFR—Rac1/Pak1/p38/MMP-2 pathway—TP53—muscle cancer	2.7e-05	0.000989	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR in Cancer—KIT—muscle cancer	2.7e-05	0.000988	CbGpPWpGaD
Docetaxel—TUBB1—Metabolism of proteins—IGF2—muscle cancer	2.69e-05	0.000985	CbGpPWpGaD
Docetaxel—EGFR—Signaling by PDGF—KIT—muscle cancer	2.69e-05	0.000984	CbGpPWpGaD
Docetaxel—Gastrointestinal disorder—Doxorubicin—muscle cancer	2.69e-05	0.000364	CcSEcCtD
Docetaxel—Fatigue—Doxorubicin—muscle cancer	2.69e-05	0.000363	CcSEcCtD
Docetaxel—EGFR—Adaptive Immune System—CD34—muscle cancer	2.68e-05	0.000981	CbGpPWpGaD
Docetaxel—Constipation—Doxorubicin—muscle cancer	2.66e-05	0.000361	CcSEcCtD
Docetaxel—Pain—Doxorubicin—muscle cancer	2.66e-05	0.000361	CcSEcCtD
Docetaxel—CYP1B1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.65e-05	0.00097	CbGpPWpGaD
Docetaxel—Hypersensitivity—Methotrexate—muscle cancer	2.65e-05	0.000359	CcSEcCtD
Docetaxel—BCL2—Focal Adhesion—VEGFA—muscle cancer	2.63e-05	0.000962	CbGpPWpGaD
Docetaxel—BCL2—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	2.62e-05	0.000958	CbGpPWpGaD
Docetaxel—EGFR—Direct p53 effectors—MDM2—muscle cancer	2.61e-05	0.000956	CbGpPWpGaD
Docetaxel—EGFR—Signaling by SCF-KIT—MDM2—muscle cancer	2.6e-05	0.00095	CbGpPWpGaD
Docetaxel—Asthenia—Methotrexate—muscle cancer	2.58e-05	0.000349	CcSEcCtD
Docetaxel—Feeling abnormal—Doxorubicin—muscle cancer	2.57e-05	0.000347	CcSEcCtD
Docetaxel—Gastrointestinal pain—Doxorubicin—muscle cancer	2.55e-05	0.000345	CcSEcCtD
Docetaxel—EGFR—B Cell Activation—KIT—muscle cancer	2.55e-05	0.000931	CbGpPWpGaD
Docetaxel—Pruritus—Methotrexate—muscle cancer	2.54e-05	0.000344	CcSEcCtD
Docetaxel—BCL2—Direct p53 effectors—TP53—muscle cancer	2.54e-05	0.000928	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling of activated FGFR—MDM2—muscle cancer	2.49e-05	0.000909	CbGpPWpGaD
Docetaxel—Abdominal pain—Doxorubicin—muscle cancer	2.46e-05	0.000333	CcSEcCtD
Docetaxel—Body temperature increased—Doxorubicin—muscle cancer	2.46e-05	0.000333	CcSEcCtD
Docetaxel—Diarrhoea—Methotrexate—muscle cancer	2.46e-05	0.000333	CcSEcCtD
Docetaxel—EGFR—Integrated Breast Cancer Pathway—MDM2—muscle cancer	2.46e-05	0.0009	CbGpPWpGaD
Docetaxel—EGFR—Signaling by NGF—FOXO1—muscle cancer	2.46e-05	0.000899	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB4—MDM2—muscle cancer	2.45e-05	0.000895	CbGpPWpGaD
Docetaxel—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	2.44e-05	0.000891	CbGpPWpGaD
Docetaxel—TUBB4A—Metabolism of proteins—IGF2—muscle cancer	2.42e-05	0.000885	CbGpPWpGaD
Docetaxel—BCL2—Integrated Breast Cancer Pathway—TP53—muscle cancer	2.39e-05	0.000873	CbGpPWpGaD
Docetaxel—Dizziness—Methotrexate—muscle cancer	2.38e-05	0.000322	CcSEcCtD
Docetaxel—BCL2—Innate Immune System—FOXO1—muscle cancer	2.37e-05	0.000868	CbGpPWpGaD
Docetaxel—BCL2—Apoptosis—TP53—muscle cancer	2.34e-05	0.000855	CbGpPWpGaD
Docetaxel—EGFR—Downstream signal transduction—MDM2—muscle cancer	2.34e-05	0.000855	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR—MDM2—muscle cancer	2.33e-05	0.00085	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	2.32e-05	0.000849	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB2—MDM2—muscle cancer	2.31e-05	0.000846	CbGpPWpGaD
Docetaxel—EGFR—DAP12 signaling—MDM2—muscle cancer	2.3e-05	0.000842	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways in Glioblastoma—TP53—muscle cancer	2.3e-05	0.000841	CbGpPWpGaD
Docetaxel—Hypersensitivity—Doxorubicin—muscle cancer	2.29e-05	0.000311	CcSEcCtD
Docetaxel—Vomiting—Methotrexate—muscle cancer	2.29e-05	0.00031	CcSEcCtD
Docetaxel—EGFR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	2.27e-05	0.00083	CbGpPWpGaD
Docetaxel—Rash—Methotrexate—muscle cancer	2.27e-05	0.000307	CcSEcCtD
Docetaxel—Dermatitis—Methotrexate—muscle cancer	2.27e-05	0.000307	CcSEcCtD
Docetaxel—Headache—Methotrexate—muscle cancer	2.25e-05	0.000305	CcSEcCtD
Docetaxel—Asthenia—Doxorubicin—muscle cancer	2.23e-05	0.000303	CcSEcCtD
Docetaxel—TUBB—Cell Cycle, Mitotic—CDKN2A—muscle cancer	2.23e-05	0.000815	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—KIT—muscle cancer	2.22e-05	0.00081	CbGpPWpGaD
Docetaxel—TUBB4B—Metabolism of proteins—IGF2—muscle cancer	2.21e-05	0.000809	CbGpPWpGaD
Docetaxel—Pruritus—Doxorubicin—muscle cancer	2.2e-05	0.000298	CcSEcCtD
Docetaxel—EGFR—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	2.17e-05	0.000792	CbGpPWpGaD
Docetaxel—EGFR—DAP12 interactions—MDM2—muscle cancer	2.17e-05	0.000792	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR in disease—MDM2—muscle cancer	2.17e-05	0.000792	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—FH—muscle cancer	2.16e-05	0.00079	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR—MDM2—muscle cancer	2.15e-05	0.000785	CbGpPWpGaD
Docetaxel—Nausea—Methotrexate—muscle cancer	2.14e-05	0.000289	CcSEcCtD
Docetaxel—Diarrhoea—Doxorubicin—muscle cancer	2.13e-05	0.000288	CcSEcCtD
Docetaxel—EGFR—Signaling by EGFR in Cancer—MDM2—muscle cancer	2.13e-05	0.000778	CbGpPWpGaD
Docetaxel—EGFR—Signaling by PDGF—MDM2—muscle cancer	2.12e-05	0.000775	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—KIDINS220—muscle cancer	2.11e-05	0.000773	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—FH—muscle cancer	2.09e-05	0.000764	CbGpPWpGaD
Docetaxel—Dizziness—Doxorubicin—muscle cancer	2.06e-05	0.000279	CcSEcCtD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	2.04e-05	0.000745	CbGpPWpGaD
Docetaxel—EGFR—B Cell Activation—MDM2—muscle cancer	2.01e-05	0.000733	CbGpPWpGaD
Docetaxel—TUBB—Cell Cycle—CDKN2A—muscle cancer	1.99e-05	0.000729	CbGpPWpGaD
Docetaxel—Vomiting—Doxorubicin—muscle cancer	1.98e-05	0.000268	CcSEcCtD
Docetaxel—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	1.98e-05	0.000724	CbGpPWpGaD
Docetaxel—BCL2—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.98e-05	0.000724	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	1.97e-05	0.000719	CbGpPWpGaD
Docetaxel—Rash—Doxorubicin—muscle cancer	1.96e-05	0.000266	CcSEcCtD
Docetaxel—Dermatitis—Doxorubicin—muscle cancer	1.96e-05	0.000266	CcSEcCtD
Docetaxel—Headache—Doxorubicin—muscle cancer	1.95e-05	0.000264	CcSEcCtD
Docetaxel—TUBB—Cell Cycle—MDM2—muscle cancer	1.93e-05	0.000707	CbGpPWpGaD
Docetaxel—EGFR—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	1.92e-05	0.000702	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—FH—muscle cancer	1.9e-05	0.000695	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—FOXO4—muscle cancer	1.9e-05	0.000695	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—FH—muscle cancer	1.88e-05	0.000689	CbGpPWpGaD
Docetaxel—EGFR—Signaling by NGF—KIT—muscle cancer	1.87e-05	0.000685	CbGpPWpGaD
Docetaxel—BCL2—Immune System—FOXO4—muscle cancer	1.87e-05	0.000684	CbGpPWpGaD
Docetaxel—EGFR—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	1.87e-05	0.000683	CbGpPWpGaD
Docetaxel—Nausea—Doxorubicin—muscle cancer	1.85e-05	0.00025	CcSEcCtD
Docetaxel—TUBB4A—Cell Cycle, Mitotic—CDKN2A—muscle cancer	1.85e-05	0.000676	CbGpPWpGaD
Docetaxel—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	1.83e-05	0.000669	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—FOXO4—muscle cancer	1.82e-05	0.000667	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—KIT—muscle cancer	1.81e-05	0.000661	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—MDM2—muscle cancer	1.75e-05	0.000638	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—MED12—muscle cancer	1.73e-05	0.000632	CbGpPWpGaD
Docetaxel—EGFR—Spinal Cord Injury—TP53—muscle cancer	1.72e-05	0.000629	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle, Mitotic—CDKN2A—muscle cancer	1.69e-05	0.000618	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle—CDKN2A—muscle cancer	1.65e-05	0.000604	CbGpPWpGaD
Docetaxel—EGFR—Immune System—CD34—muscle cancer	1.63e-05	0.000595	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle—MDM2—muscle cancer	1.6e-05	0.000586	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—FOXO1—muscle cancer	1.59e-05	0.000581	CbGpPWpGaD
Docetaxel—ABCB1—Allograft Rejection—VEGFA—muscle cancer	1.58e-05	0.000579	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—ENO2—muscle cancer	1.57e-05	0.000576	CbGpPWpGaD
Docetaxel—EGFR—Focal Adhesion—VEGFA—muscle cancer	1.55e-05	0.000568	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.55e-05	0.000566	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—CDKN2A—muscle cancer	1.51e-05	0.000553	CbGpPWpGaD
Docetaxel—EGFR—Direct p53 effectors—TP53—muscle cancer	1.5e-05	0.000548	CbGpPWpGaD
Docetaxel—EGFR—Signaling by NGF—MDM2—muscle cancer	1.48e-05	0.00054	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—MDM2—muscle cancer	1.47e-05	0.000536	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—MDM2—muscle cancer	1.42e-05	0.000521	CbGpPWpGaD
Docetaxel—EGFR—Integrated Breast Cancer Pathway—TP53—muscle cancer	1.41e-05	0.000516	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—PTCH1—muscle cancer	1.41e-05	0.000515	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—FOXO1—muscle cancer	1.4e-05	0.000513	CbGpPWpGaD
Docetaxel—BCL2—Immune System—FOXO1—muscle cancer	1.38e-05	0.000505	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—FH—muscle cancer	1.36e-05	0.000498	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—FOXO1—muscle cancer	1.35e-05	0.000493	CbGpPWpGaD
Docetaxel—ABCC1—Disease—ENO2—muscle cancer	1.33e-05	0.000486	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—VEGFA—muscle cancer	1.33e-05	0.000485	CbGpPWpGaD
Docetaxel—EGFR—MAPK Signaling Pathway—TP53—muscle cancer	1.3e-05	0.000474	CbGpPWpGaD
Docetaxel—EGFR—Disease—ENO2—muscle cancer	1.25e-05	0.000458	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.23e-05	0.00045	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—MED12—muscle cancer	1.22e-05	0.000447	CbGpPWpGaD
Docetaxel—ABCC1—Disease—HMGA1—muscle cancer	1.21e-05	0.000442	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—CNR1—muscle cancer	1.19e-05	0.000435	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—MED12—muscle cancer	1.18e-05	0.000432	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.17e-05	0.000428	CbGpPWpGaD
Docetaxel—EGFR—Disease—HMGA1—muscle cancer	1.14e-05	0.000416	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—ENO2—muscle cancer	1.11e-05	0.000407	CbGpPWpGaD
Docetaxel—TUBB—Cell Cycle—TP53—muscle cancer	1.11e-05	0.000406	CbGpPWpGaD
Docetaxel—EGFR—Immune System—FOXO4—muscle cancer	1.11e-05	0.000405	CbGpPWpGaD
Docetaxel—ABCC1—Disease—FOXO4—muscle cancer	1.08e-05	0.000396	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—ENO2—muscle cancer	1.08e-05	0.000394	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—MED12—muscle cancer	1.07e-05	0.000393	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—KIT—muscle cancer	1.07e-05	0.000391	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—MED12—muscle cancer	1.07e-05	0.000389	CbGpPWpGaD
Docetaxel—BCL2—Immune System—KIT—muscle cancer	1.05e-05	0.000385	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	1.03e-05	0.000376	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—FH—muscle cancer	1.03e-05	0.000376	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—KIT—muscle cancer	1.03e-05	0.000375	CbGpPWpGaD
Docetaxel—EGFR—Disease—FOXO4—muscle cancer	1.02e-05	0.000374	CbGpPWpGaD
Docetaxel—EGFR—Axon guidance—VEGFA—muscle cancer	1.01e-05	0.000371	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—TP53—muscle cancer	1e-05	0.000366	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	9.92e-06	0.000363	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—ENO2—muscle cancer	9.8e-06	0.000358	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—ENO2—muscle cancer	9.71e-06	0.000355	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle—TP53—muscle cancer	9.19e-06	0.000336	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	8.71e-06	0.000318	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	8.42e-06	0.000308	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—MDM2—muscle cancer	8.42e-06	0.000308	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—TP53—muscle cancer	8.41e-06	0.000308	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—PTCH1—muscle cancer	8.32e-06	0.000304	CbGpPWpGaD
Docetaxel—BCL2—Immune System—MDM2—muscle cancer	8.29e-06	0.000303	CbGpPWpGaD
Docetaxel—EGFR—Immune System—FOXO1—muscle cancer	8.17e-06	0.000299	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—MDM2—muscle cancer	8.08e-06	0.000296	CbGpPWpGaD
Docetaxel—ABCC1—Disease—FOXO1—muscle cancer	8e-06	0.000293	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	7.81e-06	0.000286	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—MED12—muscle cancer	7.7e-06	0.000282	CbGpPWpGaD
Docetaxel—EGFR—Disease—FOXO1—muscle cancer	7.54e-06	0.000276	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—VEGFA—muscle cancer	7.24e-06	0.000265	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—FOXO4—muscle cancer	7.15e-06	0.000262	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CNR1—muscle cancer	7.02e-06	0.000257	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—ENO2—muscle cancer	7.02e-06	0.000257	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—FH—muscle cancer	6.33e-06	0.000232	CbGpPWpGaD
Docetaxel—EGFR—Immune System—KIT—muscle cancer	6.23e-06	0.000228	CbGpPWpGaD
Docetaxel—ABCC1—Disease—KIT—muscle cancer	6.1e-06	0.000223	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	5.9e-06	0.000216	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—MED12—muscle cancer	5.81e-06	0.000212	CbGpPWpGaD
Docetaxel—EGFR—Disease—KIT—muscle cancer	5.75e-06	0.00021	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—IGF2—muscle cancer	5.74e-06	0.00021	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—PTGS2—muscle cancer	5.48e-06	0.000201	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—ENO2—muscle cancer	5.3e-06	0.000194	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—FOXO1—muscle cancer	5.28e-06	0.000193	CbGpPWpGaD
Docetaxel—EGFR—Immune System—MDM2—muscle cancer	4.9e-06	0.000179	CbGpPWpGaD
Docetaxel—ABCC1—Disease—MDM2—muscle cancer	4.8e-06	0.000176	CbGpPWpGaD
Docetaxel—ABCC1—Disease—PTGS2—muscle cancer	4.63e-06	0.000169	CbGpPWpGaD
Docetaxel—EGFR—Disease—MDM2—muscle cancer	4.53e-06	0.000166	CbGpPWpGaD
Docetaxel—EGFR—Disease—PTGS2—muscle cancer	4.36e-06	0.00016	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—KIT—muscle cancer	4.02e-06	0.000147	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—PTGS2—muscle cancer	3.88e-06	0.000142	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PTGS2—muscle cancer	3.75e-06	0.000137	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—MED12—muscle cancer	3.58e-06	0.000131	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PTGS2—muscle cancer	3.41e-06	0.000125	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PTGS2—muscle cancer	3.38e-06	0.000124	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ENO2—muscle cancer	3.26e-06	0.000119	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—MDM2—muscle cancer	3.17e-06	0.000116	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PTGS2—muscle cancer	2.44e-06	8.94e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—VEGFA—muscle cancer	2.41e-06	8.8e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PTGS2—muscle cancer	1.84e-06	6.75e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—TP53—muscle cancer	1.82e-06	6.65e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PTGS2—muscle cancer	1.14e-06	4.16e-05	CbGpPWpGaD
